The present disclosure relates generally to devices and methods to selectively couple tubular members, particularly in medical devices. More specifically, the present disclosure relates to drainage stent delivery systems comprising a catheter and a stent that can be percutaneously inserted into a patient, after which the stent can be remotely decoupled from the catheter.
The embodiments disclosed herein will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. These drawings depict only typical embodiments, which will be described with additional specificity and detail through use of the accompanying drawings in which:
Drainage stents can be used to drain fluid from various cavities and/or organs within a patient. In certain instances, a drainage stent is a medical device used within a patient population that experience one or more complications associated with the urinary system, including the kidneys, ureters, and/or bladder. In some instances, complications may affect urinary flow and how these organs handle this function. These complications range from decreased urine flow to swelling of the kidneys or bladder. Many of these conditions are adversely impacted by the formation of kidney stones. To alleviate urinary system complications, a drainage stent delivery system may be used to deliver a ureteral stent to within the bladder, one or both of the kidneys, and/or one or both of the ureters.
The drainage stent delivery system can include a catheter body, a drainage stent member, and a coupling member. The coupling member is configured to selectively couple and decouple the drainage stent member from the catheter body. The coupling member is also configured to facilitate rotation of the catheter body and the stent member in a 1:1 ratio, such as while the system is being delivered into a patient. In other words, when coupled, the catheter body and the stent member can be rotationally fixed. In certain embodiments, the coupling member can include a first or proximal connector coupled to a distal end of the catheter body, a distal or second connector coupled to a proximal end of the stent member, and a telescoping connector slidably coupled to the first and second connectors. The first connector includes a tab configured to be received by a slot of the second connector. The telescoping connector displaces the tab radially outward to be disposed within the slot when the catheter body and the stent member are coupled together. To decouple the stent member from the catheter body, the telescoping connector is retracted from the first and second connectors, the tab is biased radially inward to displace the tab from the slot, and the catheter body and the stent member can be separated.
In an exemplary use, the drainage stent delivery system can be percutaneously inserted into a patient's body such that a distal end of the drainage stent is positioned within the patient's bladder and the proximal end is positioned within the patient's kidney. A body of the stent member can be disposed in the patient's ureter between the kidney and the bladder. The stent member can be used to drain the kidney when there is a blockage or restriction of the ureter. Following a period of time, for example two weeks, to allow stabilization of the stent member, the catheter body may be remotely decoupled from the stent member, by retracting a cable coupled to the telescoping connector, and removed from the patient without surgical intervention. In some embodiments, the stent member may include retention features, for example pigtails, at the proximal and distal ends.
In other applications, the drainage stent delivery system may be used to drain bile from the patient's liver or gall bladder into the patient's small intestine, where the stent member is disposed within a blocked or restricted bile duct. In still other applications, the drainage stent delivery system may be used to drain any suitable organ of the patient where a natural drainage tube or duct is blocked or restricted. For example, the drainage stent delivery system may be used to drain fluid from a patient's cranial cavity, pericardial cavity, pleural cavity, etc.
Embodiments may be understood by reference to the drawings, wherein like parts are designated by like numerals throughout. It will be readily understood by one of ordinary skill in the art having the benefit of this disclosure that the components of the embodiments, as generally described and illustrated in the figures herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the figures, is not intended to limit the scope of the disclosure, but is merely representative of various embodiments. While the various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
It will be appreciated that various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. Many of these features may be used alone and/or in combination with one another.
The phrases “coupled to” and “in communication with” refer to any form of interaction between two or more entities, including mechanical, electrical, magnetic, electromagnetic, fluid, and thermal interaction. Two components may be coupled to or in communication with each other even though they are not in direct contact with each other. For example, two components may be coupled to or in communication with each other through an intermediate component.
The directional terms “distal” and “proximal” are given their ordinary meaning in the art. That is, the distal end of a medical device means the end of the device furthest from the practitioner during use. The proximal end refers to the opposite end, or the end nearest the practitioner during use. As specifically applied to the drainage stent delivery system, the proximal end of the system refers to the end that extends from the patient's body and the distal end refers to the opposite end, the end disposed within the patient's organ to be drained. For example, the patient's bladder. Thus, if at one or more points in a procedure the practitioner changes the orientation of the system, as used herein, the term “proximal end” always refers to the end of the system extending from the patient's body (even if the distal end is temporarily closer to the practitioner).
“Fluid” is used in its broadest sense, to refer to any fluid, including both liquids and gases as well as solutions, compounds, suspensions, etc., which generally behave as fluids.
As further depicted in the embodiment of
In the depicted embodiment of
When the stent member 130 is in an unrestricted state, as shown in
As depicted in the embodiment of
The tab 153 is shown to extend from a distal end of the first connector 151. In the illustrated embodiment, the first connector 151 includes two tabs 153 disposed circumferentially 180 degrees from each other. In other embodiments, the first connector 151 may include a single tab 153. In another embodiment, the first connector 151 may include three, four, five, or more tabs 153. The tab 153 is in a shape of a “T” with a cross portion disposed at a distal end of a longitudinal elongate portion. In other embodiments, the tab 153 may be of any suitable shape where a distal portion of the tab 153 is larger than a proximal portion. For example, the distal portion of the tab 153 may have a circular, oval, elliptical, triangular, square, polygonal, shape, etc. In a natural state, the tab 153 may be biased radially inward as depicted in
As illustrated in
The slot 162 is shown disposed in a proximal end of the body 161. The illustrated embodiment of
The telescoping connector 170 can be disposed within bores or lumens of the first connector 151 and the second connector 160. The telescoping connector 170 can be a hollow cylinder made from any suitable material, such as metallic materials, including, but not limited to, stainless steel, titanium, and shape memory metals or metal alloys, such as nickel titanium alloy, copper aluminum nickel alloy, iron manganese silicon alloy, copper zinc aluminum alloy, etc. An outer diameter of the telescoping connector 170 is smaller than inner diameters of the bores of the first and second connectors 151, 160 to facilitate disposing of the telescoping connector 170 within the bores when the first and second connectors 151, 160 are coupled together and retraction of the telescoping connector 170 from the first and second connectors 151, 160 to enable decoupling of the first and second connectors 151, 160 from one another. An elongate cable 171 is coupled to the telescoping connector 170 to facilitate retraction of the telescoping connector 170 from the first and second connectors 151, 160. Various types of elongate cables 171 can be used. In some embodiments, the elongate cable 171 comprises a plurality of strands wound together.
In another embodiment of a drainage stent delivery system 100a, as depicted in
The telescoping connector 170 can be configured to displace the tab 153 radially outward, as shown in
When in the coupled configuration, the lumens of the tubular member 111 and the tubular body 131 are aligned by the coupling member 150. Additionally, rotation of the catheter body 110 to position the stent member 130 within the patient's body can cause an equal rotation of the stent member 130. In other words, the catheter body 110 and the stent member 130 can be rotated at a 1:1 ratio as the drainage stent delivery system 100 is inserted into the patient's body. For instance, the tab 153 can engage the slot 162 to rotate the stent member 130 as the catheter body 110 is rotated. When coupled, the stent member 130 and catheter 110 can be described as being rotationally fixed.
As shown in
The drainage stent delivery system 100 may be utilized to drain urine from the patient's kidney into the bladder when the patient's ureter is blocked or restricted. In some embodiments, the drainage stent delivery system may be used to drain bile from the patient's liver or gall bladder into the patient's small intestine, where the stent member is disposed within a blocked or restricted bile duct. In other embodiments, the drainage stent delivery system 100 may be utilized to drain any suitable body cavity, such as the cranial cavity, the pericardial cavity, the pleural cavity, etc.
An exemplary use of a drainage stent delivery system is to drain urine from the patient's kidney into the bladder when the patient's ureter is blocked or restricted. The drainage stent delivery system may be inserted into the patient over a previously inserted guidewire. A distal portion of the stent may be positioned in the bladder and a proximal portion positioned in the kidney. A body of the stent member can be disposed within a blocked or restricted ureter. Positioning of the stent member may require rotation of the stent member. A coupling member that selectively couples the stent member and a catheter body together can facilitate equal rotation of the catheter body and the stent member. The coupling member may include a proximal connector having a tab, a distal connector having a slot to receive the tab, and a telescoping connector removably disposed within the proximal and distal connectors. The telescoping connector can displace the tab radially outward and into the slot. Upon removal of the guidewire, retention members, such as pigtails, of the proximal and distal portions of the stent may form (automatically or manually) to retain the distal portion in the bladder and the proximal portion within the kidney.
A proximal portion of the catheter body can extend outside of the patient's body. A fluid drainage container may be coupled to a hub of the catheter body to collect the urine drained from the kidney and/or bladder. The drainage stent delivery system may remain indwelling for a period of time ranging from about one week to about three weeks. The catheter body may be decoupled from the stent member by proximally retracting the telescoping connector from the first and second connectors. For example, the telescoping connector can be retracted by a proximally directed force applied to a cable coupled to the telescoping connector. Upon retraction of the telescoping connector, the tab is biased radially inward and displaced from the slot. The catheter body is separated from the stent member and the catheter body is removed from the patient, leaving the stent member in place.
Any methods disclosed herein comprise one or more steps or actions for performing the described method. The method steps and/or actions may be interchanged with one another. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order and/or use of specific steps and/or actions may be modified.
References to approximations are made throughout this specification, such as by use of the term “substantially.” For each such reference, it is to be understood that, in some embodiments, the value, feature, or characteristic may be specified without approximation. For example, where qualifiers such as “about” and “substantially” are used, these terms include within their scope the qualified words in the absence of their qualifiers. For example, where the term “substantially perpendicular” is recited with respect to a feature, it is understood that in further embodiments, the feature can have a precisely perpendicular configuration.
Similarly, in the above description of embodiments, various features are sometimes grouped together in a single embodiment, figure, or description thereof for the purpose of streamlining the disclosure. This method of disclosure, however, is not to be interpreted as reflecting an intention that any claim require more features than those expressly recited in that claim. Rather, as the following claims reflect, inventive aspects lie in a combination of fewer than all features of any single foregoing disclosed embodiment.
The claims following this written disclosure are hereby expressly incorporated into the present written disclosure, with each claim standing on its own as a separate embodiment. This disclosure includes all permutations of the independent claims with their dependent claims. Moreover, additional embodiments capable of derivation from the independent and dependent claims that follow are also expressly incorporated into the present written description.
Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the invention to its fullest extent. The claims and embodiments disclosed herein are to be construed as merely illustrative and exemplary, and not a limitation of the scope of the present disclosure in any way. It will be apparent to those having ordinary skill in the art, with the aid of the present disclosure, that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the disclosure herein. In other words, various modifications and improvements of the embodiments specifically disclosed in the description above are within the scope of the appended claims. Moreover, the order of the steps or actions of the methods disclosed herein may be changed by those skilled in the art without departing from the scope of the present disclosure. In other words, unless a specific order of steps or actions is required for proper operation of the embodiment, the order or use of specific steps or actions may be modified. The scope of the invention is therefore defined by the following claims and their equivalents.
This application claims priority to U.S. Provisional Application No. 63/010,521, filed Apr. 15, 2020, and titled SYSTEMS AND METHODS FOR COUPLING AND DECOUPLING A CATHETER, which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
818817 | Leva | Apr 1906 | A |
3996938 | Clark, III | Dec 1976 | A |
4350161 | Davis, Jr. | Sep 1982 | A |
4790810 | Pugh, Jr. et al. | Dec 1988 | A |
4813925 | Anderson, Jr. et al. | Mar 1989 | A |
4830003 | Wolff et al. | May 1989 | A |
4913683 | Gregory | Apr 1990 | A |
4957479 | Roemer | Sep 1990 | A |
4963129 | Rusch | Oct 1990 | A |
5002560 | Machold et al. | Mar 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5071407 | Termin et al. | Dec 1991 | A |
5122136 | Guglielmi | Jun 1992 | A |
5221253 | Coll | Jun 1993 | A |
5250069 | Nobuyoshi et al. | Oct 1993 | A |
5259847 | Trambert | Nov 1993 | A |
5282784 | Willard | Feb 1994 | A |
5354263 | Coll | Oct 1994 | A |
5364340 | Coll | Nov 1994 | A |
5456667 | Ham et al. | Oct 1995 | A |
5507732 | McClure et al. | Apr 1996 | A |
5507751 | Goode et al. | Apr 1996 | A |
5599291 | Balbierz et al. | Feb 1997 | A |
5643254 | Scheldrup et al. | Jul 1997 | A |
5653684 | Laptewicz et al. | Aug 1997 | A |
5846251 | Hart | Dec 1998 | A |
5876417 | Devonec et al. | Mar 1999 | A |
5921952 | Desmond, III et al. | Jul 1999 | A |
5964771 | Beyar et al. | Oct 1999 | A |
6074339 | Gambale et al. | Jun 2000 | A |
6196996 | Teirstein | Mar 2001 | B1 |
6248100 | De Toledo et al. | Jun 2001 | B1 |
6264624 | Desmond, III et al. | Jul 2001 | B1 |
6319287 | Frimberger | Nov 2001 | B1 |
6562024 | De Toledo et al. | May 2003 | B2 |
6569150 | Teague et al. | May 2003 | B2 |
6576008 | Devonec et al. | Jun 2003 | B2 |
6629981 | Dennis et al. | Oct 2003 | B2 |
6673106 | Mitelberg et al. | Jan 2004 | B2 |
6676651 | Haacke et al. | Jan 2004 | B2 |
6913625 | Segura et al. | Jul 2005 | B2 |
6929664 | Kolb et al. | Aug 2005 | B2 |
6949125 | Robertson | Sep 2005 | B2 |
6991614 | McWeeney et al. | Jan 2006 | B2 |
7044980 | Hammond et al. | May 2006 | B2 |
7044981 | Liu et al. | May 2006 | B2 |
7169139 | Teague et al. | Jan 2007 | B2 |
7217250 | Kolb et al. | May 2007 | B2 |
7367987 | Balgobin et al. | May 2008 | B2 |
7371252 | Balgobin et al. | May 2008 | B2 |
7377932 | Mitelberg et al. | May 2008 | B2 |
7550002 | Goto et al. | Jun 2009 | B2 |
7566316 | McGuckin, Jr. et al. | Jul 2009 | B2 |
7722604 | Brown, III et al. | May 2010 | B2 |
7731676 | Maeda | Jun 2010 | B2 |
7811305 | Balgobin et al. | Oct 2010 | B2 |
7824367 | Accisano, III | Nov 2010 | B2 |
7901704 | Richard | Mar 2011 | B2 |
7901444 | Slazas | May 2011 | B2 |
7993329 | Howell et al. | Aug 2011 | B2 |
8007540 | Robertson | Aug 2011 | B2 |
8021434 | Segura et al. | Sep 2011 | B2 |
8034094 | Aoba et al. | Oct 2011 | B2 |
8070825 | Devonec | Dec 2011 | B2 |
8298276 | Ozawa et al. | Oct 2012 | B2 |
8333000 | Huang et al. | Dec 2012 | B2 |
8333796 | Tompkins et al. | Dec 2012 | B2 |
8603185 | Shah et al. | Dec 2013 | B2 |
8657884 | Smouse | Feb 2014 | B2 |
8676349 | Stalker et al. | Mar 2014 | B2 |
8702784 | Weisman et al. | Apr 2014 | B2 |
8753303 | Weisman et al. | Jun 2014 | B2 |
8771335 | Griego et al. | Jul 2014 | B2 |
8961518 | Taylor et al. | Feb 2015 | B2 |
8961581 | Taylor et al. | Feb 2015 | B2 |
8979824 | Amos et al. | Mar 2015 | B2 |
8986364 | Okuma | Mar 2015 | B2 |
9026229 | Stalker et al. | May 2015 | B2 |
9186151 | Tompkins et al. | Nov 2015 | B2 |
9265637 | Weisman et al. | Feb 2016 | B2 |
9308359 | Ward | Apr 2016 | B2 |
9314359 | Windheuser et al. | Apr 2016 | B2 |
9387312 | Smouse et al. | Jul 2016 | B2 |
9510962 | Aoba et al. | Dec 2016 | B2 |
9517120 | Devonec et al. | Dec 2016 | B2 |
9597207 | Weisman et al. | Mar 2017 | B2 |
9956100 | Smouse et al. | May 2018 | B2 |
10310098 | Qiang et al. | Jun 2019 | B1 |
20020055767 | Forde et al. | May 2002 | A1 |
20030069533 | Kakutani et al. | Apr 2003 | A1 |
20030163204 | Rix | Aug 2003 | A1 |
20030191450 | Teague et al. | Oct 2003 | A1 |
20030195456 | Robertson | Oct 2003 | A1 |
20040073283 | Ewers | Apr 2004 | A1 |
20040098105 | Stinson et al. | May 2004 | A1 |
20040181186 | Gellman et al. | Sep 2004 | A1 |
20040249343 | Cioanta | Dec 2004 | A1 |
20050085892 | Goto et al. | Apr 2005 | A1 |
20070078446 | Lavelle et al. | Apr 2007 | A1 |
20070112420 | Laduca | May 2007 | A1 |
20070219612 | Andreas et al. | Sep 2007 | A1 |
20070233223 | Styrc et al. | Oct 2007 | A1 |
20070276466 | Lavelle et al. | Nov 2007 | A1 |
20080109059 | Gordon et al. | May 2008 | A1 |
20080140101 | Carley | Jun 2008 | A1 |
20080221554 | O'Connor et al. | Sep 2008 | A1 |
20090048654 | Chmura et al. | Feb 2009 | A1 |
20090088833 | Soetermans | Apr 2009 | A1 |
20090099640 | Weng | Apr 2009 | A1 |
20090105719 | Honey et al. | Apr 2009 | A1 |
20090248169 | Li | Oct 2009 | A1 |
20090312829 | Aoba et al. | Dec 2009 | A1 |
20100070047 | Smouse | Mar 2010 | A1 |
20100182271 | Krier | Jul 2010 | A1 |
20100185271 | Zhang | Jul 2010 | A1 |
20100268201 | Tieu et al. | Oct 2010 | A1 |
20110009950 | Grandfield et al. | Jan 2011 | A1 |
20110071621 | Griego et al. | Mar 2011 | A1 |
20110077622 | Weisman et al. | Mar 2011 | A1 |
20110130821 | Styrc | Jun 2011 | A1 |
20110190862 | Bashiri et al. | Aug 2011 | A1 |
20110196410 | Besselink et al. | Aug 2011 | A1 |
20110196507 | St. Pierre | Aug 2011 | A1 |
20110282249 | Tsoref et al. | Nov 2011 | A1 |
20110282429 | Shin et al. | Nov 2011 | A1 |
20110288624 | Roeder et al. | Nov 2011 | A1 |
20110295265 | Hollett et al. | Dec 2011 | A1 |
20110313404 | Amos et al. | Dec 2011 | A1 |
20120041538 | White et al. | Feb 2012 | A1 |
20120095567 | Weisman et al. | Apr 2012 | A1 |
20120203325 | Weisman et al. | Aug 2012 | A1 |
20120330397 | Harrison et al. | Dec 2012 | A1 |
20130110042 | Humphreys et al. | May 2013 | A1 |
20130204344 | Tatalovich et al. | Aug 2013 | A1 |
20130254751 | Phung et al. | Sep 2013 | A1 |
20140114431 | Yamagata | Apr 2014 | A1 |
20140135941 | Smouse et al. | May 2014 | A1 |
20140172065 | Lavelle et al. | Jun 2014 | A1 |
20140194970 | Chobotov | Jul 2014 | A1 |
20140200462 | Stalker et al. | Jul 2014 | A1 |
20140309721 | Griego et al. | Oct 2014 | A1 |
20150005864 | Okuma | Jan 2015 | A1 |
20150073525 | Aoba et al. | Mar 2015 | A1 |
20150157480 | Amos et al. | Jun 2015 | A1 |
20150223953 | Pendleton et al. | Aug 2015 | A1 |
20160015509 | McDonough | Jan 2016 | A1 |
20160045347 | Smouse et al. | Feb 2016 | A1 |
20160120675 | Weisman et al. | May 2016 | A1 |
20160135941 | Binmoeller et al. | May 2016 | A1 |
20160151615 | Overtoom | Jun 2016 | A1 |
20160184123 | Windheuser et al. | Jun 2016 | A1 |
20160287372 | Smouse et al. | Oct 2016 | A1 |
20160361167 | Tuval et al. | Dec 2016 | A1 |
20180325709 | Tatalovich et al. | Nov 2018 | A1 |
20210007870 | Smouse et al. | Jan 2021 | A1 |
20210322190 | Accisano, III | Oct 2021 | A1 |
20210378850 | Accisano, III | Dec 2021 | A1 |
Number | Date | Country |
---|---|---|
2128148 | Mar 1993 | CN |
2408894 | Dec 2000 | CN |
201624817 | Nov 2010 | CN |
102548505 | Jul 2012 | CN |
102579171 | Jul 2012 | CN |
102596083 | Jul 2012 | CN |
202537720 | Nov 2012 | CN |
202637201 | Jan 2013 | CN |
103211671 | Jul 2013 | CN |
103876872 | Jun 2014 | CN |
103961194 | Aug 2014 | CN |
0806189 | Nov 1997 | EP |
2002071765 | Mar 2002 | JP |
2003530165 | Oct 2003 | JP |
2009297502 | Dec 2009 | JP |
2012239803 | Dec 2012 | JP |
2015073547 | Apr 2015 | JP |
198805317 | Jul 1988 | WO |
199611721 | Apr 1996 | WO |
2013003450 | Jan 2013 | WO |
2015108609 | Jul 2015 | WO |
2016025434 | Feb 2016 | WO |
2016042150 | Mar 2016 | WO |
2018156650 | Aug 2018 | WO |
Entry |
---|
Office Action dated Feb. 10, 2022 for U.S. Appl. No. 15/901,833. |
Final Office Action dated Mar. 4, 2022 received in U.S. Appl. No. 15/958,406 (10 pages). |
International Search Report and Written Opinion dated Jul. 26, 2021 for PCT/US2021/026886. |
Office Action dated May 26, 2022 for U.S. Appl. No. 15/901,833. |
Office Action dated Sep. 19, 2019 for U.S. Appl. No. 15/901,833. |
Office Action dated Apr. 21, 2021 for U.S. Appl. No. 15/958,406. |
Office Action dated May 28, 2021 for U.S. Appl. No. 15/901,833. |
Office Action dated Aug. 17, 2021 for U.S. Appl. No. 15/958,406. |
Extended European Search Report dated Dec. 9, 2021 for EP21191048.4. |
Office Action dated Mar. 4, 2022 for U.S. Appl. No. 15/958,406. |
European Search Report dated May 19, 2020 for EP15831895.6. |
European Search Report dated Sep. 7, 2017 for EP14878890.4. |
European Search Report dated Dec. 22, 2017 for EP15831895.6. |
European Search Report dated Dec. 22, 2020 for EP18758123.6. |
International Search Report and Written Opinion dated Jan. 7, 2016 for PCT/US2015/44580. |
International Search Report and Written Opinion dated Mar. 25, 2015 for PCT/US2014/063758. |
International Search Report and Written Opinion dated Jun. 15, 2018 for PCT/US2018/19045. |
Notice of Allowance dated Jan. 16, 2018 for U.S. Appl. No. 14/823,243. |
Notice of Allowance dated Mar. 26, 2018 for U.S. Appl. No. 14/823,243. |
Notice of Allowance dated Apr. 20, 2020 for U.S. Appl. No. 15/936,856. |
Notice of Allowance dated Apr. 27, 2020 for U.S. Appl. No. 15/175,436. |
Notice of Allowance dated May 13, 2016 for U.S. Appl. No. 14/159,221. |
Notice of Allowance dated Oct. 9, 2013 for U.S. Appl. No. 12/559,946. |
Office Action dated Jan. 3, 2012 for U.S. Appl. No. 12/559,946. |
Office Action dated Jan. 10, 2020 for U.S. Appl. No. 15/936,856. |
Office Action dated Feb. 5, 2021 for U.S. Appl. No. 15/901,833. |
Office Action dated Feb. 12, 2020 for U.S. Appl. No. 15/901,833. |
Office Action dated Feb. 26, 2016 for U.S. Appl. No. 14/159,221. |
Office Action dated Apr. 18, 2017 for U.S. Appl. No. 14/823,243. |
Office Action dated Apr. 22, 2020 for U.S. Appl. No. 15/958,406. |
Office Action dated Aug. 7, 2020 for U.S. Appl. No. 15/958,406. |
Office Action dated Aug. 31, 2017 for U.S. Appl. No. 14/823,243. |
Office Action dated Sep. 4, 2020 for U.S. Appl. No. 15/901,833. |
Office Action dated Sep. 9, 2019 for U.S. Appl. No. 15/175,436. |
Office Action dated Oct. 7, 2015 for U.S. Appl. No. 14/159,221. |
Office Action dated Oct. 21, 2019 for U.S. Appl. No. 15/958,406. |
Office Action dated Oct. 24, 2012 for U.S. Appl. No. 12/559,946. |
Office Action dated Dec. 31, 2019 for U.S. Appl. No. 15/175,436. |
Notice of Allowance dated Nov. 8, 2023 for U.S. Appl. No. 16/937,280. |
Office Action dated Jan. 12, 2023 for U.S. Appl. No. 15/901,833. |
European Search Report dated May 31, 2024 for EP21818001.6. |
Extended European Search Report dated May 3, 2024 for EP21788557.3. |
Number | Date | Country | |
---|---|---|---|
20210322190 A1 | Oct 2021 | US |
Number | Date | Country | |
---|---|---|---|
63010521 | Apr 2020 | US |